Newsletters

[NPJ Precision Oncology] The authors performed an integrated multi-omics analysis combining bulk transcriptomics, single-cell RNA sequencing, and spatial transcriptomics to systematically investigate the expression pattern and functional relevance of myristoylated alanine-rich C kinase substrate (MARCKS) in HCC.

[Naunyn-Schmiedebergs Archives of Pharmacology] Researchers investigated the modulatory effect of ingerone on AQP9 expression in a steatosis cell model through experimental and in silico analyses, providing insights that could contribute to therapeutic interventions for nonalcoholic fatty liver disease.

[Biochemical and Biophysical Research Communications] The authors synthesize current literature on mitochondrial dysfunction and chronic inflammation in metabolic dysfunction-associated steatohepatitis/metabolic dysfunction-associated steatotic liver disease (MASH/MASLD), examine the critical role of intrahepatic intercellular communication, particularly via extracellular vesicles, and highlight targeting mitochondria as a promising therapeutic strategy for MASH.

[Hepion Pharmaceuticals, Inc.] Hepion Pharmaceuticals, Inc. announced that it has in-licensed from Cirna Diagnostics LLC, a novel biomarker assay that detects mutant circulating tumor RNA to facilitate early diagnosis of HCC in high-risk patients.

[Advanced Materials] Investigators introduced an airway-on-tube that integrates an engineered ECM hydrogel, tuned to match lung tissue stiffness, with a tubular melt electrowritten scaffold.

[Novocure] Novocure announced that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua^® through the country’s National Health Insurance coverage.

[British Journal of Pharmacology] Researchers investigated an intermediate subpopulation of alveolar epithelial cells, termed “Regeneration Alveolar Epithelial cells“, which reached a peak 14 days post-injury.